In a competitive binding assay using purified Flag-CRBN, inert opto-pomalidomide was largely ineffective at binding CRBN, in contrast to free Pomalidomide. Incubation with Pomalidomide increased p21WAF-1 expression in parental U266 cells. In MM.1SCRBN+/+ and MM.1SCRBN−/− cells, Pomalidomide reduced proliferation in a CRBN-dependent manner. [1,2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Pomalidomide binding to purified CRBN
Cell-based study · Flag-CRBN purified from human embryonic kidney (HEK) 293T cells [1]
A competitive binding assay used Flag-CRBN purified from human embryonic kidney (HEK) 293T cells. Inert opto-pomalidomide was largely ineffective at binding CRBN, in contrast to free Pomalidomide.
Literature-Reported Treatment Conditions
- Exposure duration
- 1 hour at 4°C
- Reported limits
- Not stated in the sentences used: dose, route, vehicle.
Methods and source locations
Compound reported in the paper: Pomalidomide
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
RESULTS > Design of opto-pomalidomide as a parent lead compound for opto-PROTAC (S9); MATERIALS AND METHODS > In vitro pulldown assays (S140); Fig. 1 legend (S156, S157)
competitive binding assay: competitive binding assay; comparator: the inert opto-pomalidomide — RESULTS > Design of opto-pomalidomide as a parent lead compound for opto-PROTAC (S9); Fig. 1 legend (S156)
Pomalidomide increases tumor suppressor expression in parental cells
Cell-based study · parental U266 cells [2]
In parental U266 cells, incubation with Pomalidomide increased expression of the tumor suppressor p21WAF-1 relative to control-treated baselines.
Literature-Reported Treatment Conditions
- Exposure duration
- 48 h
- Method
- incubation
- Reported limits
- Not stated in the sentences used: dose, vehicle.
Methods and source locations
Compound reported in the paper: Pomalidomide
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > CRBN short hairpin RNA reduces the effects of lenalidomide and pomalidomide in myeloma cells (S55); Figure 2 legend (S107, S108)
Expression of the tumor suppressor p21WAF-1: Expression of the tumor suppressor p21WAF-1; comparator: control-treated baselines — Results > CRBN short hairpin RNA reduces the effects of lenalidomide and pomalidomide in myeloma cells (S55); Figure 2 legend (S107)
CRBN-Dependent Reduction in Cell Proliferation
Cell-based study · MM.1SCRBN+/+ and MM.1SCRBN−/− cells [1]
Pomalidomide was evaluated in MM.1SCRBN+/+ and MM.1SCRBN−/− cells using a CCK-8 cell viability assay. Pomalidomide reduced MM.1S cell proliferation in a CRBN-dependent manner.
Literature-Reported Treatment Conditions
- Exposure duration
- 72 hours
- Reported limits
- Not stated in the sentences used: dose, route, vehicle, control.
Methods and source locations
Compound reported in the paper: Pomalidomide
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
MATERIALS AND METHODS > CCK-8 cell proliferation assay (S148); Fig. 2 legend (S171, S172)
CCK-8 cell viability assay: CCK-8 cell viability assay — Fig. 2 legend (S171, S172)